Brief: Elicera Therapeutics Q2 Operating Loss SEK 6.3 Mln
28/08/2026 07:16
BRIEF-Elicera Therapeutics Q2 Operating Loss SEK 6.3 Mln Aug 28 (Reuters) - Elicera Therapeutics AB ELIC.ST:
Q2 ADJUSTED EPS SEK -0.12
Q2 LOSS AMOUNTED TO SEK -6,305,471 (-2,892,341)
Q2 OPERATING LOSS AMOUNTED TO SEK -6,305,471 (-2,892,341)
Q2 LOSS FOR PERIOD AMOUNTED TO SEK -6,261,763 (-2,732,070)
Source text: ID:nWkr8F1Mwz
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application